Gapping down
In reaction to disappointing earnings/guidance: LQDT -16.2%, SSI -11.5%, EDAP -10.1%, JKS -8.2%, SMTC -7.5%, UNH -6.1%, BBY -4.2%, BKE -1.5%, SMRT -1.2%, IGLD -1%
M&A news: SYT -2.3% (cont volatility surrounding M&A spec)
Other news: NBG -17.1% (cont weakness), AMAG -10.2% (received Complete Response Letter from the FDA for Makena (hydroxyprogesterone caproate injection) for the reduction of the risk of preterm birth), VLP -9.1% (announces an underwritten public offering of 4.25 mln units ), SUNE -4.9% (Blackstone denying speculation related to debt investment), AET -4.1% (in symp with UNH), RDY -2.8% ( issues statement related to recent media reports; co states it has always adhered to international accounting practices), HUM -2.4% (in symp with UNH), AGN -1.8% (Allergan, Pfizer (PFE) near a deal under which Pfizer would acquire Allergan for as much as $380/share, according to BloombergWSJ reporting Treasury Department might issue anti inversion tax rules this week), DVA -1.6% (co's subsidiary received Civil Investigative Demand from the U.S. Department of Justice), RMAX -1.6% (prices secondary offering of 4,500,000 shares of common stock by its controlling stockholder, RIHI, at $36.00 per share), EQIX -1.6% (prices offering of 2,604,167 shares of common stock at $288.00 per share), BFAM -1.5% (announces pricing of its 3.65 mln share secondary offering by selling stockholders at $63.80/share)
Analyst comments: TWI -7.7% (downgraded to Sell from Neutral at Goldman
)
In reaction to disappointing earnings/guidance: LQDT -16.2%, SSI -11.5%, EDAP -10.1%, JKS -8.2%, SMTC -7.5%, UNH -6.1%, BBY -4.2%, BKE -1.5%, SMRT -1.2%, IGLD -1%
M&A news: SYT -2.3% (cont volatility surrounding M&A spec)
Other news: NBG -17.1% (cont weakness), AMAG -10.2% (received Complete Response Letter from the FDA for Makena (hydroxyprogesterone caproate injection) for the reduction of the risk of preterm birth), VLP -9.1% (announces an underwritten public offering of 4.25 mln units ), SUNE -4.9% (Blackstone denying speculation related to debt investment), AET -4.1% (in symp with UNH), RDY -2.8% ( issues statement related to recent media reports; co states it has always adhered to international accounting practices), HUM -2.4% (in symp with UNH), AGN -1.8% (Allergan, Pfizer (PFE) near a deal under which Pfizer would acquire Allergan for as much as $380/share, according to BloombergWSJ reporting Treasury Department might issue anti inversion tax rules this week), DVA -1.6% (co's subsidiary received Civil Investigative Demand from the U.S. Department of Justice), RMAX -1.6% (prices secondary offering of 4,500,000 shares of common stock by its controlling stockholder, RIHI, at $36.00 per share), EQIX -1.6% (prices offering of 2,604,167 shares of common stock at $288.00 per share), BFAM -1.5% (announces pricing of its 3.65 mln share secondary offering by selling stockholders at $63.80/share)
Analyst comments: TWI -7.7% (downgraded to Sell from Neutral at Goldman
)
Gapping up
In reaction to strong earnings/guidance: GMCR +19.1%, GFI +15.7%, CTRP +12%, WB +8.4%, CRM +4.9%, CRH +4.6%, PERY +4%, NTAP +2.1%, SINA +1.9%, CVO +0.6%, SJM +0.5%
M&A news: CLDN +64.9% (Celladon and Eiger BioPharmaceuticals sign merger agreement; concurrent financing of $39.5 million from investor syndicate), BZC +3.5% (TransDigm Group Incorporated (TDG) and Breeze-Eastern agree to an acquisition of Breeze-Eastern for $19.61/share in cash)
Select small cap biotech related names showing strength: MCUR +32.5%, CAPN +20.8%, SPHS +8.9%, PHMD +3.6%, APPY +3.2%, ORMP +3%, SNTA +2.8%
Select metals/mining stocks trading higher: MTL +7.3%, AU +3.6%, MT +2.9%, BHP +1.7%, BBL +1.3%, RIO +1.2%, AA +1.1%, VALE +1%, GDX +0.6%
Other news: KBIO +663.8% (Former Retrophin CEO and current Turing Pharma CEO Martin Shkreli discloses ownership of ~1.625 mln shares; ~1.2 mln shares purchased from 11/16 to 11/17 at prices ranging from $0.30-2.45 per share ), STEM +53.8% (announces that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury showed motor improvements in both strength and function), NLST +51.5% (entered into a five year Joint Development and License Agreement w/ Samsung Electronics (SSNLF) to produce a new class of NVDIMM-P memory solutions), UNXL +34% (receives initial mass production order from Japanese PC manufacturer), VTAE +23.3% (announced positive top-line results from a Phase 1 multiple ascending dose trial of VTP-43742; shown to be safe and generally well tolerated in healthy human volunteers), SFXE +23.2% (light volume, pre-mkt rebound following yday's news), HART +21.9% (small cap biotech peer; CFO disclosed small purchase last night -- 10K shares), VTL +15.7% (received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial), VBLT +13% (announces significant improvement of 12 Month overall survival with VB-111), TUMI +6.5% (to replace IPCM in the S&P SmallCap 600), PLPM +6.4% (signs multi-currency processing agreement with BBVA Bancomer and launches its integrated payments hospitality solution for BBVA Bancomer merchants ), ATHX +4% (reports that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury), ZIOP +3.8% (will present initial results from its Phase 1 dose-escalation study of Ad-RTS-hIL-12), RTN +2.9% (affirms $0.67/share quarterly dividend, adds $2 bln to repurchase program ), FIT +2.4% (favorable commentary on Wednesday's Mad Money), CETV +2.3% (TCS Capital Management discloses 10.9% active stake in 13D filing; TCS sends letter to Board urging pursuit of strategic alternatives), CLLS +1.7% (Servier Exercises signs exclusive worldwide licensing option with Cellectis for UCART19), VOD +1.3% (announces its intention to raise around £500 million of new debt issuance of non-dilutive equity-linked bonds due 2020), DAL +1% (announces its intention to acquire up to an additional 32% of the outstanding capital stock of Grupo Aeromexico S.A.B. through a cash tender offer for MXP$43.59/share)
Analyst comments: TTPH +8.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), WEN +2.8% (added to Conviction Buy List at Goldman), NGG +1.4% (upgraded to Outperform at RBC Capital Mkts), SUN +1.3% (upgraded to Outperform from Neutral at Credit Suisse)
In reaction to strong earnings/guidance: GMCR +19.1%, GFI +15.7%, CTRP +12%, WB +8.4%, CRM +4.9%, CRH +4.6%, PERY +4%, NTAP +2.1%, SINA +1.9%, CVO +0.6%, SJM +0.5%
M&A news: CLDN +64.9% (Celladon and Eiger BioPharmaceuticals sign merger agreement; concurrent financing of $39.5 million from investor syndicate), BZC +3.5% (TransDigm Group Incorporated (TDG) and Breeze-Eastern agree to an acquisition of Breeze-Eastern for $19.61/share in cash)
Select small cap biotech related names showing strength: MCUR +32.5%, CAPN +20.8%, SPHS +8.9%, PHMD +3.6%, APPY +3.2%, ORMP +3%, SNTA +2.8%
Select metals/mining stocks trading higher: MTL +7.3%, AU +3.6%, MT +2.9%, BHP +1.7%, BBL +1.3%, RIO +1.2%, AA +1.1%, VALE +1%, GDX +0.6%
Other news: KBIO +663.8% (Former Retrophin CEO and current Turing Pharma CEO Martin Shkreli discloses ownership of ~1.625 mln shares; ~1.2 mln shares purchased from 11/16 to 11/17 at prices ranging from $0.30-2.45 per share ), STEM +53.8% (announces that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury showed motor improvements in both strength and function), NLST +51.5% (entered into a five year Joint Development and License Agreement w/ Samsung Electronics (SSNLF) to produce a new class of NVDIMM-P memory solutions), UNXL +34% (receives initial mass production order from Japanese PC manufacturer), VTAE +23.3% (announced positive top-line results from a Phase 1 multiple ascending dose trial of VTP-43742; shown to be safe and generally well tolerated in healthy human volunteers), SFXE +23.2% (light volume, pre-mkt rebound following yday's news), HART +21.9% (small cap biotech peer; CFO disclosed small purchase last night -- 10K shares), VTL +15.7% (received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial), VBLT +13% (announces significant improvement of 12 Month overall survival with VB-111), TUMI +6.5% (to replace IPCM in the S&P SmallCap 600), PLPM +6.4% (signs multi-currency processing agreement with BBVA Bancomer and launches its integrated payments hospitality solution for BBVA Bancomer merchants ), ATHX +4% (reports that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury), ZIOP +3.8% (will present initial results from its Phase 1 dose-escalation study of Ad-RTS-hIL-12), RTN +2.9% (affirms $0.67/share quarterly dividend, adds $2 bln to repurchase program ), FIT +2.4% (favorable commentary on Wednesday's Mad Money), CETV +2.3% (TCS Capital Management discloses 10.9% active stake in 13D filing; TCS sends letter to Board urging pursuit of strategic alternatives), CLLS +1.7% (Servier Exercises signs exclusive worldwide licensing option with Cellectis for UCART19), VOD +1.3% (announces its intention to raise around £500 million of new debt issuance of non-dilutive equity-linked bonds due 2020), DAL +1% (announces its intention to acquire up to an additional 32% of the outstanding capital stock of Grupo Aeromexico S.A.B. through a cash tender offer for MXP$43.59/share)
Analyst comments: TTPH +8.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), WEN +2.8% (added to Conviction Buy List at Goldman), NGG +1.4% (upgraded to Outperform at RBC Capital Mkts), SUN +1.3% (upgraded to Outperform from Neutral at Credit Suisse)
Early premarket gappers
Gapping up: KBIO +1011.1%, CLDN +147.7%, STEM +75.8%, MCUR +45.1%, GFI +24.9%, VTAE +23.3%, SFXE +23.2%, GMCR +16.7%, CTRP +13.6%, WB +10.4%, AU +6.9%, PLPM +6.4%, TUMI +6.4%, CRM +6.1%, CRH +5.1%, JKS +3.4%, RTN +3.3%, MT +3.3%, CRNT +2.9%, BHP +2.8%, CLLS +2.8%, BBL +2.6%, RIO +2.3%, SINA +2.3%, SDRL +2.2%, FIT +2.2%, RDS.A +2.2%,SHPG +2%, ING +2%, GDX +1.8%, NTAP +1.8%, BKE +1.8%, DB +1.7%, PYPL +1.6%, RIG +1.4%, GOLD +1.4%, VOD +1.3%, BP +1.2%, AA +1.1%, VALE +1%, LB +0.8%, CVO +0.6%
Gapping down: NBG -19.1%, AMAG -11%, TWI -9.9%, SUNE -9.2%, VLP -7.6%, SMTC -7.2%, BBY -6.6%, UNH -6.2%, CETV -6.1%, SSI -6.1%, EDAP -5.6%, RDY -2.8%, DVA -1.6%, YNDX -1.6%, SYT -1.6%, RMAX -1.5%, CGEN -1.4%, EQIX -1.1%, IGLD -1%, AGN -0.7%
Gapping down: NBG -19.1%, AMAG -11%, TWI -9.9%, SUNE -9.2%, VLP -7.6%, SMTC -7.2%, BBY -6.6%, UNH -6.2%, CETV -6.1%, SSI -6.1%, EDAP -5.6%, RDY -2.8%, DVA -1.6%, YNDX -1.6%, SYT -1.6%, RMAX -1.5%, CGEN -1.4%, EQIX -1.1%, IGLD -1%, AGN -0.7%
NYSE to eliminate "stop orders" from February
{http://www.lefigaro.fr/economie/le-scan-eco/dessous-chiffres/2015/11/19/29006-20151119ARTFIG00006-petrole-taxes-donations-trafics-d-humains-comment-daech-se-finance.php}
--> A good war is a always a good solution to solve a debt issue...
could weight on SANFOI
(MergerMarket)
No major complications are expected from Australia’s Foreign Investment Review Board (FIRB) to the proposed acquisition by Royal Dutch Shell [LON:RDSA] of BG Group [LON: BG], it was said.
Earlier Thursday, the Australian Competition and Consumer Commission (ACCC) said it would not oppose the proposed acquisition, leaving FIRB and China’s MOFCOM as the last remaining regulatory hurdles.
Following clearances in Brazil and the EU, three of the five pre-conditions to the combination have now been satisfied.
In its statement, Shell said the filing process in China continues to progress well and the combination remains on track for completion in early 2016.
FIRB typically waits for an ACCC decision before starting its process, which can take up to 30 days. Shell has been in dialogue with FIRB and it was said that FIRB’s process can be expected to kick off soon and complete before Christmas.
The CEO of the Energy Users Association of Australia (EUAA), Phillip Barresi, has said that the association is not going to raise any issues regarding the merger with FIRB. The EUAA made two submissions to the ACCC calling for behavioural undertakings to accompany any structural undertakings.
The EUAA considers itself the main lobby group representing energy users and the only one entirely focused around energy issues. EUAA lists 67 members, including Australia’s largest groups such as Rio Tinto [LON/ASX:RIO], Bluescope [ASX:BSL], Glencore [LON:GLEN], Incitec Pivot [ASX:IPL] and Wesfarmers.
Other energy user industry groups - Manufacturing Australia and Major Energy Users (MEU) – had submitted concerns to the ACCC that the proposed takeover will reduce competition in the Australian East Coast gas market but did not make a fresh submission after the ACCC issued its Statement of Issues (SOI) in September.
Shell declined to comment when contacted by this news service.